Natera

Today, we celebrate genetic counselors! 🧬 We're especially proud of the incredible team of over 150 genetic counselors (GCs) at Natera. These highly-trained professionals provide support to patients and families navigating genetic testing – with empathy as the cornerstone of every interaction. 💙💚 In addition to patient-facing roles, our GCs apply their diverse skills across the company, contributing to business development, research, training, and more. Natera GCs also support the GC community through educational events such as exam study groups, professional development opportunities, and resume clinics. Thank you, GCs, for all that you do! 👏 https://ow.ly/4fib50U71WA #GeneticCounselors #PatientCare #GCAwarenessDay #Natera

Are you interested in becoming a genetic counselor or have a desire to learn about lab-based genetic counseling roles? 🧬🥼🔬 Please join us for a webinar exploring some of the roles that genetic counselors may have working for a commercial lab. This event will feature four panelists who are eager to discuss their various roles and how their career path led them to #Natera. #GeneticCounselor Wednesday, November 13 4 PM ET | 1 PM PT View the full details below and register today: https://ow.ly/JuLb50U1OS5

#Natera co-founder and executive chairman of the board, Matthew Rabinowitz, PhD, has been named a finalist in the Leadership category for the California Life Sciences (CLS) Pantheon Award. The award recognizes leaders who innovate in life sciences, demonstrating commitment to positive global impact and support for patient-centric initiatives. Winners are selected by public voting now through October 15th. Please cast your vote at https://lnkd.in/eGPkm4xA by selecting the leadership category at the bottom. #PantheonAwards

Up to 30% of breast cancer survivors will face a recurrence, sometimes years after treatment. Our #Signatera test detects molecular residual disease – tiny traces of cancer cells that can remain in the body after treatment and may lead to recurrence. It can detect these signs months before imaging, giving survivors and their cancer care team more time to act. Stay ahead of recurrence – learn how Signatera can support long-term health today. https://lnkd.in/e_ZDnXd9 #BreastCancer

#Natera co-founder and executive chairman of the board, Matthew Rabinowitz, PhD, has been named a finalist in the Leadership category for the California Life Sciences (CLS) Annual Pantheon Awards. This recognition follows his recent honor as R&D Leader of the Year by R&D World. 👏 The Pantheon award celebrates California leaders making valuable contributions across the pharmaceutical, biotech and other industries. Winners are selected by public voting, which is open now through October 15th. Cast your vote here: https://ow.ly/TRKX50TBIYj

October is #NationalBreastCancerAwarenessMonth, but it's about more than awareness...it's about action. We need everyone to join us in spreading the message -- from advocating for early detection to supporting research and equitable care for all, your voice matters. Follow along with us here all month long or visit komen.org to find out how to join our fight. Because ending breast cancer needs all of us.

I previously discussed Natera’s 200+ peer-reviewed papers and transformational moments in healthcare. We are at another such milestone: The release of data from Circulate Japan in simultaneous papers in Nature Medicine and Annals of Oncology. The studies demonstrate a 10x overall survival improvement for Signatera-positive vs. negative colorectal cancer (CRC) patients and that we can at last decipher who should and shouldn’t receive chemotherapy after tumor removal. This technology can potentially save the U.S. healthcare system more than any single drug repricing in the Inflation Reduction Act and save many patients the side-effect and emotional burden of unnecessary chemo. This has already led to updates in the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines, marking a significant shift in global care. Congrats and thanks to the superb team at Natera; we’ve surpassed 85 peer-reviewed publications on Signatera alone. #ColorectalCancer #CancerResearch #CancerTreatment #HealthcareInnovation #CancerGuidelines #MedTech

#NSGC24 Cancer Special Interest Group (SIG) Happy Hour | Driving Hereditary Cancer Testing & Precision Patient Management in Oncology Join Natera on Sept. 19th for a taste of New Orleans and to preview our new hereditary cancer program offerings. Explore customizable gene and panel options, and patient access support with the Natera Empower Hereditary Cancer Test. Learn about the new Hereditary Cancer Alert Program (HCAP) utilizing the Signatera Residual Disease Test (MRD), which increased at-risk patients receiving hereditary cancer testing by 200% in a pilot study. Register here👉 https://ow.ly/2uzu50Thx4H #Natera #Oncology #HereditaryCancer

#NSGC24 Learning Theater | Katherine Krepkovich, medical science liaison at Natera, will present data from the largest clinical validation study for #FetalRhD to date in the US, with >650 Rh negative pregnant people and confirmation by serology on all newborns. 🤰 Register here👉 https://ow.ly/GWQC50TfOhT #Natera #RhD #NIPT #GeneticCounselor

“ESMO 2024 will showcase some of our most impactful data in colorectal cancer to-date,” said Minetta Liu, MD, chief medical officer of oncology at Natera. “Notably, we will present an updated analysis from the GALAXY arm of CIRCULATE-Japan with the first prospective read-out of overall survival based on MRD. These findings underscore the potential for Signatera to predict long-term outcomes.” #ESMO24